Skip to main content
SpringerLink
Log in

Management of Ventricular Arrhythmias in Heart Failure

  • Published:
Current Heart Failure Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Despite substantial progress in medical and device-based heart failure (HF) therapy, ventricular arrhythmias (VA) and sudden cardiac death (SCD) remain a major challenge. Here we review contemporary management of VA in the context of HF with one particular focus on recent advances in imaging and catheter ablation.

Recent Findings

Besides limited efficacy of antiarrhythmic drugs (AADs), their potentially life-threatening side effects are increasingly acknowledged. On the other hand, with tremendous advances in catheter technology, electroanatomical mapping, imaging, and understanding of arrhythmia mechanisms, catheter ablation has evolved into a safe, efficacious therapy. In fact, recent randomized trials support early catheter ablation, demonstrating superiority over AAD. Importantly, CMR imaging with gadolinium contrast has emerged as a central tool for the management of VA complicating HF: CMR is not only essential for an accurate diagnosis of the underlying entity and subsequent treatment decisions, but also improves risk stratification for SCD prevention and patient selection for ICD therapy. Finally, 3-dimensional characterization of arrhythmogenic substrate by CMR and imaging-guided ablation approaches substantially enhance procedural safety and efficacy.

Summary

VA management in HF patients is highly complex and should be addressed in a multidisciplinary approach, preferably at specialized centers. While recent evidence supports early catheter ablation of VA, an impact on mortality remains to be demonstrated. Moreover, risk stratification for ICD therapy may have to be reconsidered, taking into account imaging, genetic testing, and other parameters beyond left ventricular function.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43:3997–4126.

    Article  PubMed  Google Scholar 

  2. Lip GY, Heinzel FR, Gaita F, Juanatey JR, Le Heuzey JY, Potpara T, et al. European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace. 2016;18:12–36.

    Article  PubMed  Google Scholar 

  3. Shen L, Jhund PS, Petrie MC, Claggett BL, Barlera S, Cleland JGF, et al. Declining risk of sudden death in heart failure. N Engl J Med. 2017;377:41–51.

    Article  PubMed  Google Scholar 

  4. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599–726.

    Article  CAS  PubMed  Google Scholar 

  5. Hennig A, Salel M, Sacher F, Camaioni C, Sridi S, Denis A, et al. High-resolution three-dimensional late gadolinium-enhanced cardiac magnetic resonance imaging to identify the underlying substrate of ventricular arrhythmia. Europace. 2018;20:f179–91.

    Article  PubMed  Google Scholar 

  6. Chen J, Johnson G, Hellkamp AS, Anderson J, Mark DB, Lee KL, et al. Rapid-rate nonsustained ventricular tachycardia found on implantable cardioverter-defibrillator interrogation: relationship to outcomes in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). J Am Coll Cardiol. 2013;61:2161–8.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Packer DL, Prutkin JM, Hellkamp AS, Mitchell LB, Bernstein RC, Wood F, et al. Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. Circulation. 2009;120:2170–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Younis A, Goldberger JJ, Kutyifa V, Zareba W, Polonsky B, Klein H, et al. Predicted benefit of an implantable cardioverter-defibrillator: the MADIT-ICD benefit score. Eur Heart J. 2021;42:1676–84. This article established and validated a score that predicts the likelihood of benefit from prophylactic ICD implantation

    Article  PubMed  PubMed Central  Google Scholar 

  9. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–37.

    Article  CAS  PubMed  Google Scholar 

  10. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–83.

    Article  PubMed  Google Scholar 

  11. Klem I, Klein M, Khan M, Yang EY, Nabi F, Ivanov A, et al. Relationship of LVEF and myocardial scar to long-term mortality risk and mode of death in patients with nonischemic cardiomyopathy. Circulation. 2021;143:1343–58. This study shows that the extent of LV fibrosis, as assessed by LGE-CMR, predicts all-cause mortality and cardiac death in patients with non-ischemic cardiomyopathy with a higher predictive value than LVEF.

    Article  CAS  PubMed  Google Scholar 

  12. Klem I, Weinsaft JW, Bahnson TD, Hegland D, Kim HW, Hayes B, et al. Assessment of myocardial scarring improves risk stratification in patients evaluated for cardiac defibrillator implantation. J Am Coll Cardiol. 2012;60:408–20.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Sánchez-Somonte P, Quinto L, Garre P, Zaraket F, Alarcón F, Borràs R, et al. Scar channels in cardiac magnetic resonance to predict appropriate therapies in primary prevention. Heart Rhythm. 2021;18:1336–43. This article provides evidence that LGE-CMR-detected scar channels predict adequate ICD therapies and freedom from arrhythmia recurrence, respectively.

    Article  PubMed  Google Scholar 

  14. Zegard A, Okafor O, de Bono J, Kalla M, Lencioni M, Marshall H, et al. Myocardial fibrosis as a predictor of sudden death in patients with coronary artery disease. J Am Coll Cardiol. 2021;77:29–41. In this study in patients with coronary artery disease, LV fibrosis as assessed by LGE-CMR was more strongly associated with ventricular arrhythmias and sudden cardiac death than LVEF.

    Article  PubMed  Google Scholar 

  15. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018;138:e210–71.

    PubMed  Google Scholar 

  16. Bing R, Dweck MR. Myocardial fibrosis: why image, how to image and clinical implications. Heart. 2019;105:1832–40.

    Article  CAS  PubMed  Google Scholar 

  17. Mewton N, Liu CY, Croisille P, Bluemke D, Lima JA. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol. 2011;57:891–903.

    Article  PubMed  Google Scholar 

  18. Mont L, Roca-Luque I, Althoff TF. Ablation lesion assessment with MRI. Arrhythm Electrophysiol Rev. 2022;11:e02.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Rodrigues P, Joshi A, Williams H, Westwood M, Petersen SE, Zemrak F, et al. Diagnosis and prognosis in sudden cardiac arrest survivors without coronary artery disease: utility of a clinical approach using cardiac magnetic resonance imaging. Circ Cardiovasc Imaging. 2017;10:e006709.

    Article  PubMed  Google Scholar 

  20. Heidary S, Patel H, Chung J, Yokota H, Gupta SN, Bennett MV, et al. Quantitative tissue characterization of infarct core and border zone in patients with ischemic cardiomyopathy by magnetic resonance is associated with future cardiovascular events. J Am Coll Cardiol. 2010;55:2762–8.

    Article  PubMed  Google Scholar 

  21. Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375:1221–30.

    Article  PubMed  Google Scholar 

  22. Muser D, Nucifora G, Muser D, Nucifora G, Pieroni M, Castro SA, et al. Prognostic value of nonischemic ringlike left ventricular scar in patients with apparently idiopathic nonsustained ventricular arrhythmias. Circulation. 2021;143:1359–73.

    Article  CAS  PubMed  Google Scholar 

  23. Andreu D, Penela D, Acosta J, Fernández-Armenta J, Perea RJ, Soto-Iglesias D, et al. Cardiac magnetic resonance-aided scar dechanneling: influence on acute and long-term outcomes. Heart Rhythm. 2017;14:1121–8.

    Article  PubMed  Google Scholar 

  24. Falasconi G, Penela D, Soto-Iglesias D, Martí-Almor J, Berruezo A. Cardiac magnetic resonance and segment of origin identification algorithm streamline post-myocardial infarction ventricular tachycardia ablation. JACC Clin Electrophysiol. 2022;8:1603–8.

    Article  PubMed  Google Scholar 

  25. Jáuregui B, Soto-Iglesias D, Zucchelli G, Penela D, Ordóñez A, Terés C, et al. Arrhythmogenic substrate detection in chronic ischaemic patients undergoing ventricular tachycardia ablation using multidetector cardiac computed tomography: compared evaluation with cardiac magnetic resonance. Europace. 2021;23:82–90.

    Article  PubMed  Google Scholar 

  26. Quinto L, Sanchez P, Alarcón F, Garre P, Zaraket F, Prat-Gonzalez S, et al. Cardiac magnetic resonance to predict recurrences after ventricular tachycardia ablation: septal involvement, transmural channels, and left ventricular mass. Europace. 2021;23:1437–45.

    Article  PubMed  Google Scholar 

  27. Roca-Luque I, Van Breukelen A, Alarcon F, Garre P, Tolosana JM, Borras R, et al. Ventricular scar channel entrances identified by new wideband cardiac magnetic resonance sequence to guide ventricular tachycardia ablation in patients with cardiac defibrillators. Europace. 2020;22:598–606. This study shows that specific wideband sequences allow for high-quality and valid LGE-CMR without artefact in patients with cardiac implantable electronic devices to guide VT ablation.

    Article  PubMed  Google Scholar 

  28. Sanchez-Somonte P, Garre P, Vázquez-Calvo S, Quinto L, Borràs R, Prat S, et al. Scar conducting channel characterization to predict arrhythmogenicity during ventricular tachycardia ablation. Europace. 2023;25:989.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Soto-Iglesias D, Acosta J, Penela D, Fernández-Armenta J, Cabrera M, Martínez M, et al. Image-based criteria to identify the presence of epicardial arrhythmogenic substrate in patients with transmural myocardial infarction. Heart Rhythm. 2018;15:814–21.

    Article  PubMed  Google Scholar 

  30. Soto-Iglesias D, Penela D, Jáuregui B, Acosta J, Fernández-Armenta J, Linhart M, et al. Cardiac magnetic resonance-guided ventricular tachycardia substrate ablation. JACC Clin Electrophysiol. 2020;6:436–47.

    Article  PubMed  Google Scholar 

  31. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999;341:1882–90.

    Article  CAS  PubMed  Google Scholar 

  32. Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA. 2004;292:2874–9.

    Article  CAS  PubMed  Google Scholar 

  33. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351:2481–8.

    Article  CAS  PubMed  Google Scholar 

  34. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151–8.

    Article  CAS  PubMed  Google Scholar 

  35. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335:1933–40.

    Article  CAS  PubMed  Google Scholar 

  36. Knops RE, Olde Nordkamp LRA, Delnoy PHM, Boersma LVA, Kuschyk J, El-Chami MF, et al. Subcutaneous or transvenous defibrillator therapy. N Engl J Med. 2020;383:526–36. This study established non-inferiority of subcutaneous ICD compared to transvenous ICD with respect to device-related complications and inappropriate shocks. However, the capability for antitachycardic pacing of transvenous ICDs reduced the necessity of shocks.

    Article  PubMed  Google Scholar 

  37. Lambiase PD, Theuns DA, Murgatroyd F, Barr C, Eckardt L, Neuzil P, et al. Subcutaneous implantable cardioverter-defibrillators: long-term results of the EFFORTLESS study. Eur Heart J. 2022;43:2037–50.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361:1329–38.

    Article  PubMed  Google Scholar 

  39. Dagres N, Peek N, Leclercq C, Hindricks G. The PROFID project. Eur Heart J. 2020;41:3781–2.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Selvanayagam JB, Hartshorne T, Billot L, Grover S, Hillis GS, Jung W, et al. Cardiovascular magnetic resonance-GUIDEd management of mild to moderate left ventricular systolic dysfunction (CMR GUIDE): Study protocol for a randomized controlled trial. Ann Noninvasive Electrocardiol. 2017;22:e12420.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Leyva F, Israel CW, Singh J. Declining risk of sudden cardiac death in heart failure: fact or myth? Circulation. 2023;147:759–67.

    Article  PubMed  Google Scholar 

  42. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337:1576–1583.

  43. Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101:1297–302.

    Article  CAS  PubMed  Google Scholar 

  44. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J. 2000;21:2071–8.

    Article  CAS  PubMed  Google Scholar 

  45. Kuck KH, Cappato R, Siebels J, Rüppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102:748–54.

    Article  CAS  PubMed  Google Scholar 

  46. Clemens M, Peichl P, Wichterle D, Pavlů L, Čihák R, Aldhoon B, et al. Catheter ablation of ventricular tachycardia as the first-line therapy in patients with coronary artery disease and preserved left ventricular systolic function: long-term results. J Cardiovasc Electrophysiol. 2015;26:1105–10.

    Article  PubMed  Google Scholar 

  47. Maury P, Baratto F, Zeppenfeld K, Klein G, Delacretaz E, Sacher F, et al. Radio-frequency ablation as primary management of well-tolerated sustained monomorphic ventricular tachycardia in patients with structural heart disease and left ventricular ejection fraction over 30%. Eur Heart J. 2014;35:1479–85.

    Article  PubMed  Google Scholar 

  48. Dawson DK, Hawlisch K, Prescott G, Roussin I, Di Pietro E, Deac M, et al. Prognostic role of CMR in patients presenting with ventricular arrhythmias. JACC Cardiovasc Imaging. 2013;6:335–44.

    Article  PubMed  Google Scholar 

  49. Tzivoni D, Banai S, Schuger C, Benhorin J, Keren A, Gottlieb S, et al. Treatment of torsade de pointes with magnesium sulfate. Circulation. 1988;77:392–7.

    Article  CAS  PubMed  Google Scholar 

  50. Do DH, Bradfield J, Ajijola OA, Vaseghi M, Le J, Rahman S, et al. Thoracic epidural anesthesia can be effective for the short-term management of ventricular tachycardia storm. J Am Heart Assoc. 2017;6. https://doi.org/10.1161/JAHA.117.007080

  51. Fudim M, Qadri YJ, Waldron NH, Boortz-Marx RL, Ganesh A, Patel CB, et al. Stellate ganglion blockade for the treatment of refractory ventricular arrhythmias. JACC Clin Electrophysiol. 2020;6:562–71.

    Article  PubMed  Google Scholar 

  52. Savastano S, Dusi V, Baldi E, Rordorf R, Sanzo A, Camporotondo R, et al. Anatomical-based percutaneous left stellate ganglion block in patients with drug-refractory electrical storm and structural heart disease: a single-centre case series. Europace. 2021;23:581–6.

    Article  PubMed  Google Scholar 

  53. Tian Y, Wittwer ED, Kapa S, McLeod CJ, Xiao P, Noseworthy PA, et al. Effective use of percutaneous stellate ganglion blockade in patients with electrical storm. Circ Arrhythm Electrophysiol. 2019;12:e007118.

    Article  PubMed  Google Scholar 

  54. Vaseghi M, Barwad P, Malavassi Corrales FJ, Tandri H, Mathuria N, Shah R, et al. Cardiac sympathetic denervation for refractory ventricular arrhythmias. J Am Coll Cardiol. 2017;69:3070–80.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Muser D, Liang JJ, Castro SA, Hayashi T, Enriquez A, Troutman GS, et al. Outcomes with prophylactic use of percutaneous left ventricular assist devices in high-risk patients undergoing catheter ablation of scar-related ventricular tachycardia: a propensity-score matched analysis. Heart Rhythm. 2018;15:1500–6.

    Article  PubMed  Google Scholar 

  56. Mathuria N, Wu G, Rojas-Delgado F, Shuraih M, Razavi M, Civitello A, et al. Outcomes of pre-emptive and rescue use of percutaneous left ventricular assist device in patients with structural heart disease undergoing catheter ablation of ventricular tachycardia. J Interv Card Electrophysiol. 2017;48:27–34.

    Article  PubMed  Google Scholar 

  57. Gopinathannair R, Cornwell WK, Dukes JW, Ellis CR, Hickey KT, Joglar JA, et al. Device therapy and arrhythmia management in left ventricular assist device recipients: a scientific statement from the American Heart Association. Circulation. 2019;139:e967–89.

    Article  PubMed  Google Scholar 

  58. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989;321:406–412.

  59. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med. 1992;327:227–233.

  60. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324:781–8.

    Article  CAS  PubMed  Google Scholar 

  61. Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA. 2006;295:165–71.

    Article  CAS  PubMed  Google Scholar 

  62. Lüderitz B, Mletzko R, Jung W, Manz M. Combination of antiarrhythmic drugs. J Cardiovasc Pharmacol. 1991;17(Suppl 6):S48-52.

    PubMed  Google Scholar 

  63. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet. 1996;348:7–12.

    Article  CAS  PubMed  Google Scholar 

  64. Pacifico A, Hohnloser SH, Williams JH, Tao B, Saksena S, Henry PD, et al. Prevention of implantable-defibrillator shocks by treatment with sotalol. d, l-Sotalol Implantable Cardioverter-Defibrillator Study Group. N Engl J Med. 1999;340:1855–62.

    Article  CAS  PubMed  Google Scholar 

  65. Gottlieb SS, Weinberg M. Cardiodepressant effects of mexiletine in patients with severe left ventricular dysfunction. Eur Heart J. 1992;13:22–7.

    Article  CAS  PubMed  Google Scholar 

  66. Hoffmeister HM, Hepp A, Seipel L. Negative inotropic effect of class-I-antiarrhythmic drugs: comparison of flecainide with disopyramide and quinidine. Eur Heart J. 1987;8:1126–32.

    Article  CAS  PubMed  Google Scholar 

  67. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9–13.

  68. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385–90.

    Article  CAS  PubMed  Google Scholar 

  69. Piccini JP, Berger JS, O’Connor CM. Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials. Eur Heart J. 2009;30:1245–53.

    Article  CAS  PubMed  Google Scholar 

  70. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med. 1995;333:77–82.

    Article  CAS  PubMed  Google Scholar 

  71. Santangeli P, Muser D, Maeda S, Filtz A, Zado ES, Frankel DS, et al. Comparative effectiveness of antiarrhythmic drugs and catheter ablation for the prevention of recurrent ventricular tachycardia in patients with implantable cardioverter-defibrillators: a systematic review and meta-analysis of randomized controlled trials. Heart Rhythm. 2016;13:1552–9.

    Article  PubMed  Google Scholar 

  72. Arenal Á, Ávila P, Jiménez-Candil J, Tercedor L, Calvo D, Arribas F, et al. Substrate ablation vs antiarrhythmic drug therapy for symptomatic ventricular tachycardia. J Am Coll Cardiol. 2022;79:1441–53. This RCT demonstrated superiority of first-line VT ablation over AAD therapy, mostly driven by AAD-related adverse effects and incidence of slow VTs.

    Article  CAS  PubMed  Google Scholar 

  73. Sapp JL, Wells GA, Parkash R, Stevenson WG, Blier L, Sarrazin JF, et al. Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs. N Engl J Med. 2016;375:111–21.

    Article  CAS  PubMed  Google Scholar 

  74. Kuck KH, Schaumann A, Eckardt L, Willems S, Ventura R, Delacrétaz E, et al. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet. 2010;375:31–40.

    Article  PubMed  Google Scholar 

  75. Reddy VY, Reynolds MR, Neuzil P, Richardson AW, Taborsky M, Jongnarangsin K, et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med. 2007;357:2657–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Willems S, Tilz RR, Steven D, Kääb S, Wegscheider K, Gellér L, et al. Preventive or deferred ablation of ventricular tachycardia in patients with ischemic cardiomyopathy and implantable defibrillator (BERLIN VT): a multicenter randomized trial. Circulation. 2020;141:1057–67. This RCT was stopped prematurely for futility and failed to prove prognostic benefit of an early VT ablation strategy compared to deferred ablation. However, early VT ablation reduced VT recurrence and appropriate ICD therapies.

    Article  PubMed  Google Scholar 

  77. Della Bella P, Baratto F, Vergara P, Bertocchi P, Santamaria M, Notarstefano P, et al. Does timing of ventricular tachycardia ablation affect prognosis in patients with an implantable cardioverter defibrillator? Results From the Multicenter Randomized PARTITA Trial. Circulation. 2022;145:1829–38. This RCT found a decrease in ICD shocks and all-cause death with early VT ablation, albeit results remain to be confirmed in an adequately powered trial.

    Article  CAS  PubMed  Google Scholar 

  78. Tung R, Xue Y, Chen M, Jiang C, Shatz DY, Besser SA, et al. First-line catheter ablation of monomorphic ventricular tachycardia in cardiomyopathy concurrent with defibrillator implantation: the PAUSE-SCD randomized trial. Circulation. 2022;145:1839–49. In this RCT, catheter ablation as first-line therapy for VT reduced the combined primary endpoint of death, cardiovascular hospitalisation, and recurrent VT in a mixed cohort of patients with ischemic (35%), non-ischemic (30%), and arrhythmogenic cardiomyopathy (35%). This was predominantly driven by a reduction in VT recurrence.

    Article  CAS  PubMed  Google Scholar 

  79. Stevenson WG, Khan H, Sager P, Saxon LA, Middlekauff HR, Natterson PD, et al. Identification of reentry circuit sites during catheter mapping and radiofrequency ablation of ventricular tachycardia late after myocardial infarction. Circulation. 1993;88:1647–70.

    Article  CAS  PubMed  Google Scholar 

  80. Aziz Z, Shatz D, Raiman M, Upadhyay GA, Beaser AD, Besser SA, et al. Targeted ablation of ventricular tachycardia guided by wavefront discontinuities during sinus rhythm: a new functional substrate mapping strategy. Circulation. 2019;140:1383–97. This article introduces the concept of isochronal mapping for the identification of slow-conduction areas in sinus rhythm to be targeted by catheter ablation.

    Article  PubMed  Google Scholar 

  81. Tung R. Substrate mapping in ventricular arrhythmias. Card Electrophysiol Clin. 2019;11:657–63.

    Article  PubMed  Google Scholar 

  82. Tung R, Raiman M, Liao H, Zhan X, Chung FP, Nagel R, et al. Simultaneous endocardial and epicardial delineation of 3D reentrant ventricular tachycardia. J Am Coll Cardiol. 2020;75:884–97. This work elaborates and highlights the 3-dimensionality of VT reentry circuits.

    Article  PubMed  Google Scholar 

  83. Cronin EM, Bogun FM, Maury P, Peichl P, Chen M, Namboodiri N, et al. 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias: executive summary. Europace. 2020;22:450–95.

    Article  PubMed  Google Scholar 

  84. Cuculich PS, Schill MR, Kashani R, Mutic S, Lang A, Cooper D, et al. Noninvasive Cardiac Radiation for Ablation of Ventricular Tachycardia. N Engl J Med. 2017;377:2325–36.

    Article  PubMed  PubMed Central  Google Scholar 

  85. Futyma P, Sauer WH. Bipolar radiofrequency catheter ablation of left ventricular summit arrhythmias. Card Electrophysiol Clin. 2023;15:57–62.

    Article  PubMed  Google Scholar 

  86. Kany S, Alken FA, Schleberger R, Baran J, Luik A, Haas A, et al. Bipolar ablation of therapy-refractory ventricular arrhythmias: application of a dedicated approach. Europace. 2022;24:959–69.

    Article  PubMed  Google Scholar 

  87. Packer DL, Wilber DJ, Kapa S, Dyrda K, Nault I, Killu AM, et al. Ablation of refractory ventricular tachycardia using intramyocardial needle delivered heated saline-enhanced radiofrequency energy: a first-in-man feasibility trial. Circ Arrhythm Electrophysiol. 2022;15:e010347.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Stevenson WG, Tedrow UB, Reddy V, AbdelWahab A, Dukkipati S, John RM, et al. Infusion needle radiofrequency ablation for treatment of refractory ventricular arrhythmias. J Am Coll Cardiol. 2019;73:1413–25.

    Article  PubMed  Google Scholar 

  89. van der Ree MH, Blanck O, Limpens J, Lee CH, Balgobind BV, Dieleman EMT, et al. Cardiac radioablation-a systematic review. Heart Rhythm. 2020;17:1381–92.

    Article  PubMed  Google Scholar 

  90. Santangeli P, Muser D, Zado ES, Magnani S, Khetpal S, Hutchinson MD, et al. Acute hemodynamic decompensation during catheter ablation of scar-related ventricular tachycardia: incidence, predictors, and impact on mortality. Circ Arrhythm Electrophysiol. 2015;8:68–75.

    Article  PubMed  Google Scholar 

  91. Luni FK, Zungsontiporn N, Farid T, Malik SA, Khan S, Daniels J, et al. Percutaneous left ventricular assist device support during ablation of ventricular tachycardia: a meta-analysis of current evidence. J Cardiovasc Electrophysiol. 2019;30:886–95.

    Article  PubMed  Google Scholar 

  92. Cikes M, Jakus N, Claggett B, Brugts JJ, Timmermans P, Pouleur AC, et al. Cardiac implantable electronic devices with a defibrillator component and all-cause mortality in left ventricular assist device carriers: results from the PCHF-VAD registry. Eur J Heart Fail. 2019;21:1129–41.

    Article  PubMed  Google Scholar 

  93. Galand V, Flécher E, Auffret V, Boulé S, Vincentelli A, Dambrin C, et al. Predictors and clinical impact of late ventricular arrhythmias in patients with continuous-flow left ventricular assist devices. JACC Clin Electrophysiol. 2018;4:1166–75.

    Article  PubMed  Google Scholar 

  94. Greet BD, Pujara D, Burkland D, Pollet M, Sudhakar D, Rojas F, et al. Incidence, predictors, and significance of ventricular arrhythmias in patients with continuous-flow left ventricular assist devices: a 15-year institutional experience. JACC Clin Electrophysiol. 2018;4:257–64.

    Article  PubMed  Google Scholar 

  95. Makki N, Mesubi O, Steyers C, Olshansky B, Abraham WT. Meta-analysis of the relation of ventricular arrhythmias to all-cause mortality after implantation of a left ventricular assist device. Am J Cardiol. 2015;116:1385–90.

    Article  PubMed  Google Scholar 

  96. Hayward CS, Salamonsen R, Keogh AM, Woodard J, Ayre P, Prichard R, et al. Effect of alteration in pump speed on pump output and left ventricular filling with continuous-flow left ventricular assist device. Asaio j. 2011;57:495–500.

    Article  PubMed  Google Scholar 

  97. Vollkron M, Voitl P, Ta J, Wieselthaler G, Schima H. Suction events during left ventricular support and ventricular arrhythmias. J Heart Lung Transplant. 2007;26:819–25.

    Article  PubMed  Google Scholar 

  98. Andersen M, Videbaek R, Boesgaard S, Sander K, Hansen PB, Gustafsson F. Incidence of ventricular arrhythmias in patients on long-term support with a continuous-flow assist device (HeartMate II). J Heart Lung Transplant. 2009;28:733–5.

    Article  PubMed  Google Scholar 

  99. Cantillon DJ, Bianco C, Wazni OM, Kanj M, Smedira NG, Wilkoff BL, et al. Electrophysiologic characteristics and catheter ablation of ventricular tachyarrhythmias among patients with heart failure on ventricular assist device support. Heart Rhythm. 2012;9:859–64.

    Article  PubMed  Google Scholar 

  100. Ziv O, Dizon J, Thosani A, Naka Y, Magnano AR, Garan H. Effects of left ventricular assist device therapy on ventricular arrhythmias. J Am Coll Cardiol. 2005;45:1428–34.

    Article  PubMed  Google Scholar 

  101. Sacher F, Reichlin T, Zado ES, Field ME, Viles-Gonzalez JF, Peichl P, et al. Characteristics of ventricular tachycardia ablation in patients with continuous flow left ventricular assist devices. Circ Arrhythm Electrophysiol. 2015;8:592–7.

    Article  PubMed  Google Scholar 

  102. Mulloy DP, Bhamidipati CM, Stone ML, Ailawadi G, Bergin JD, Mahapatra S, et al. Cryoablation during left ventricular assist device implantation reduces postoperative ventricular tachyarrhythmias. J Thorac Cardiovasc Surg. 2013;145:1207–13.

    Article  PubMed  Google Scholar 

  103. Patel M, Rojas F, Shabari FR, Simpson L, Cohn W, Frazier OH, et al. Safety and feasibility of open chest epicardial mapping and ablation of ventricular tachycardia during the period of left ventricular assist device implantation. J Cardiovasc Electrophysiol. 2016;27:95–101.

    Article  PubMed  Google Scholar 

  104. Clerkin KJ, Topkara VK, Demmer RT, Dizon JM, Yuzefpolskaya M, Fried JA, et al. Implantable cardioverter-defibrillators in patients with a continuous-flow left ventricular assist device: an analysis of the INTERMACS registry. JACC Heart Fail. 2017;5:916–26.

    Article  PubMed  PubMed Central  Google Scholar 

  105. Aquaro GD, Pingitore A, Strata E, Di Bella G, Molinaro S, Lombardi M. Cardiac magnetic resonance predicts outcome in patients with premature ventricular complexes of left bundle branch block morphology. J Am Coll Cardiol. 2010;56:1235–43.

    Article  PubMed  Google Scholar 

  106. Muser D, Santangeli P, Castro SA, Casado Arroyo R, Maeda S, Benhayon DA, et al. Risk stratification of patients with apparently idiopathic premature ventricular contractions: a multicenter international CMR registry. JACC Clin Electrophysiol. 2020;6:722–35.

    Article  PubMed  Google Scholar 

  107. Yokokawa M, Siontis KC, Kim HM, Stojanovska J, Latchamsetty R, Crawford T, et al. Value of cardiac magnetic resonance imaging and programmed ventricular stimulation in patients with frequent premature ventricular complexes undergoing radiofrequency ablation. Heart Rhythm. 2017;14:1695–701.

    Article  PubMed  Google Scholar 

  108. Baldasseroni S, Opasich C, Gorini M, Lucci D, Marchionni N, Marini M, et al. Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure. Am Heart J. 2002;143:398–405.

    Article  PubMed  Google Scholar 

  109. Baman TS, Lange DC, Ilg KJ, Gupta SK, Liu TY, Alguire C, et al. Relationship between burden of premature ventricular complexes and left ventricular function. Heart Rhythm. 2010;7:865–9.

    Article  PubMed  Google Scholar 

  110. Latchamsetty R, Yokokawa M, Morady F, Kim HM, Mathew S, Tilz R, et al. Multicenter outcomes for catheter ablation of idiopathic premature ventricular complexes. JACC Clin Electrophysiol. 2015;1:116–23.

    Article  PubMed  Google Scholar 

  111. Lee AKY, Andrade J, Hawkins NM, Alexander G, Bennett MT, Chakrabarti S, et al. Outcomes of untreated frequent premature ventricular complexes with normal left ventricular function. Heart. 2019;105:1408–13.

    Article  PubMed  Google Scholar 

  112. Voskoboinik A, Hadjis A, Alhede C, Im SI, Park H, Moss J, et al. Predictors of adverse outcome in patients with frequent premature ventricular complexes: the ABC-VT risk score. Heart Rhythm. 2020;17:1066–74.

    Article  PubMed  Google Scholar 

  113. Berruezo A, Penela D, Jáuregui B, Soto-Iglesias D, Aguinaga L, Ordóñez A, et al. Mortality and morbidity reduction after frequent premature ventricular complexes ablation in patients with left ventricular systolic dysfunction. Europace. 2019;21:1079–87.

    Article  PubMed  Google Scholar 

  114. Penela D, Acosta J, Aguinaga L, Tercedor L, Ordoñez A, Fernández-Armenta J, et al. Ablation of frequent PVC in patients meeting criteria for primary prevention ICD implant: safety of withholding the implant. Heart Rhythm. 2015;12:2434–42.

    Article  PubMed  Google Scholar 

  115. Penela D, Van Huls Vans Taxis C, Aguinaga L, Fernández-Armenta J, Mont L, et al. Neurohormonal, structural, and functional recovery pattern after premature ventricular complex ablation is independent of structural heart disease status in patients with depressed left ventricular ejection fraction: a prospective multicenter study. J Am Coll Cardiol. 2013;62:1195–202.

    Article  CAS  PubMed  Google Scholar 

  116. Ling Z, Liu Z, Su L, Zipunnikov V, Wu J, Du H, et al. Radiofrequency ablation versus antiarrhythmic medication for treatment of ventricular premature beats from the right ventricular outflow tract: prospective randomized study. Circ Arrhythm Electrophysiol. 2014;7:237–43.

    Article  CAS  PubMed  Google Scholar 

  117. Hyman MC, Mustin D, Supple G, Schaller RD, Santangeli P, Arkles J, et al. Class IC antiarrhythmic drugs for suspected premature ventricular contraction-induced cardiomyopathy. Heart Rhythm. 2018;15:159–63.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Arrhythmia Section, Cardiovascular Institute (ICCV), CLÍNIC Barcelona University Hospital, C/Villarroel N° 170, 08036, Barcelona, Catalonia, Spain

    Sara Vázquez-Calvo, Ivo Roca-Luque & Till F. Althoff

  2. Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Catalonia, Spain

    Sara Vázquez-Calvo, Ivo Roca-Luque & Till F. Althoff

Authors
  1. Sara Vázquez-Calvo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ivo Roca-Luque
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Till F. Althoff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Till F. Althoff.

Ethics declarations

Conflict of Interest

The authors declare no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vázquez-Calvo, S., Roca-Luque, I. & Althoff, T.F. Management of Ventricular Arrhythmias in Heart Failure. Curr Heart Fail Rep 20, 237–253 (2023). https://doi.org/10.1007/s11897-023-00608-y

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11897-023-00608-y

Keywords

Search

Navigation